Zogenix

December 17, 2020December 17, 2020

Fintepla Found to Safely Reduce LGS Seizure Frequency

uncategorized

Fintepla (fenfluramine) safely lowered the frequency of drop seizures — those where part or all of the body may become limp — in patients with Lennox-Gastaut syndrome (LGS), according to ... Read more

February 27, 2020February 27, 2020

Fintepla Cuts Lennox-Gastaut Drop Seizure Frequency, Trial Shows

uncategorized

Fintepla (ZX008), an investigational therapy from Zogenix, significantly lowered the frequency of drop seizures and was well tolerated in children and adults with Lennox‑Gastaut syndrome, according to topline results from ... Read more

November 7, 2019November 14, 2019

Enrollment Completed in Phase 3 Trial Testing Fintepla to Treat Seizures in Lennox-Gastaut Syndrome Patients

News

Zogenix has enrolled the last patient in a Phase 3 clinical trial evaluating its lead investigational candidate Fintepla (ZX008) as an add-on therapy for seizures associated with Lennox‑Gastaut syndrome (LGS), the company ... Read more